-
-
[1]World Health Organization.Hepatitis B[DB].World Health Organi-zation Fact Sheet204. (Revised October2000) .WHO website.ht-tp://www.who.int/mediacentre/factsheets/fs204/en. [2]Hadziyannis SJ, Vassilopoulos D.Hepatitis B e antigen-negativechronic hepatitis B[J].Hepatology, 2001, 34 (4) ∶617-624. [3]Fattovich G.Natural history of hepatitis B[J].J Hepatol, 2003, 39suppl 1∶S50-S58. [4]雷春亮, 彭晓谋, 顾林, 等.HBeAg阴性慢性乙型肝炎患者出现前C区和基本核启动子联合突变的意义[J].中华传染病杂志, 2005, 23 (1) ∶10-13. [5]Liaw YF, Leng N, Guan R, et al.Asian-Pacific consensus state-ment on the management of chronic hepatitis B:a 2005 update[J].Liver Int, 2005, 25∶472-489. [6]Funk ML, Rosenberg DM, Lok ASF.Word-wide epidemiology ofHBeAg-negative chronic hepatitis B and associated precore and coreprmoter variants[J].J Viral Hepat, 2002, 9∶52-61. [7]任红.中国慢性乙型肝炎治疗策略—2004年全国乙型肝炎治疗策略专家峰会纪要[J].中华肝脏病杂志, 2005, 13 (5) ∶326-328. [8]Bonino F, Brunetto MR.Chronic hepatitis B e antigen (HBeAg) negative, anti-HBe positive hepatitis B:an overview[J].J Hepatol, 2003, 39 suppl 1∶S160-S163. [9] 骆抗先.乙型肝炎基础和临床[M].第2版.北京:人民卫生出版社, 2001∶274. [10]Papatheodoridis GV, Hadziyannis SJ.Diagnosis and management ofpre-core mutant chronic hepatitis B[J].J Viral Hepat, 2001, 8, 311-321. [11]Anna SF, Lok and Brian J.McMahon.Chronic Hepatitis B:Up-date of Recommendations[J].AASLD PRACTICE GUIDELINE.Hepatology, 2004, 39 (3) ∶857-861. [12]de Franchis R, Hadengue A.ESALinternational Consensus Confer-ence on Hepatitis B[J].J Hepatol, 2003, 39 suppl 1∶s3-s25. [13]贾继东.乙型肝炎e抗原阴性慢性乙型肝炎的治疗[J].中华肝脏病杂志, 2005, 13 (7) ∶539. [14]Lin CC, Wu JC, Chang TT, et al.Long-termevaluation of recom-binant interferon alpha2b in the treatment of patients with hepatitis Be antigen-negative chronic hepatitis B in Taiwan[J].J Viral Hepat, 2001, 8∶438-446. [15]Manesis E K, Hadziyannis S J.Interferon alpha treatment and re-treatment of hepatitis B e antigen negative chronic hepatitis B mutants[J].Gastroenterology, 2001, 121∶101-109. [16]Marcellin P, Lau GKK, Bonino F, et al.Peginterferon alfa-2a a-lone, lamivudine alone and the two in combination in patients withHBeAg negative chronic hepatitis B[J].NEngl J Med, 2004, 351∶1206-1217. [17]Lai CL, Rosmawati M, Lao J, et al.Entecavir is superior to lami-vudine in reducing hepatitis B virus DNA in patients with chronichepatitis B infection[J].Gastroenterology, 2002, 123 (6) ∶1831~1838.
本文二维码
计量
- 文章访问数: 1844
- HTML全文浏览量: 4
- PDF下载量: 840
- 被引次数: 0